GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia
Sponsor: St. Petersburg State Pavlov Medical University
This PHASE1/PHASE2 trial investigates Acute Myeloid Leukemia and Leukemia, Acute Lymphoblastic and is currently completed. St. Petersburg State Pavlov Medical University leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Apr 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- St. Petersburg State Pavlov Medical University
For direct contact, visit the study record on ClinicalTrials.gov .